A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

Published:2007-05 Issue:2 Volume:105 Page:508-516
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

McMeekin D. Scott,Sill Michael W.,Benbrook Doris,Darcy Kathleen M.,Stearns-Kurosawa Deborah J.,Eaton Lynne,Yamada S. Diane

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference45 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J. Clin.,2006

2. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;J. Clin. Oncol.,2004

3. Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24 h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study;Fleming;Ann. Oncol.,2004

4. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study;Fleming;J. Clin. Oncol.,2004

5. Whole abdominal radiotherapy versus combination doxorubicin–cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group;Randall;J. Clin. Oncol.,2006

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy;Cancers;2024-05-27

2. PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer;International Journal of Gynecologic Cancer;2024-01-06

3. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study;Annals of Translational Medicine;2023-01

4. Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer;Biomolecules;2021-12-21

5. Recurrent Endometrial Cancer: Local and Systemic Treatment Options;Cancers;2021-12-14